Indivior PLC (LON: INDV) today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. Reddy's, Actavis, Par, Alvogen and Teva for infringement of United States Patent No. 9,931,305 (the '305 patent) relating to their respective proposed generic versions of the Company's Suboxone (buprenorphine and naloxone) Sublingual Film product.

The '305 patent was issued on April 3rd and has been submitted for listing in the Orange Book. Indivior lost a patent case in March of 2018 on other patents ('514, '150, and '497). The United States District Court for the District of Delaware ruled that Alvogen's generic version of Suboxone Film did not infringe upon those patents.

At the time of the ruling, Indivior said that the ruling would result in a "rapid and material loss of market share." In addition to Suboxone Film, Indivior's portfolio also includes Sublocade.  Sublocade is a subcutaneous injection form of buprenorphine and is used to treat opioid dependence.